Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,745 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A set of genes associated with the interferon-γ response of lung cancer patients undergoing α-galactosylceramide-pulsed dendritic cell therapy.
Okita K, Motohashi S, Shinnakasu R, Nagato K, Yamasaki K, Sato Y, Kitamura H, Hijikata A, Yamashita M, Shimizu K, Fujii S, Ohara O, Taniguchi M, Sakaida I, Nakayama T. Okita K, et al. Among authors: yamasaki k. Cancer Sci. 2010 Nov;101(11):2333-40. doi: 10.1111/j.1349-7006.2010.01696.x. Cancer Sci. 2010. PMID: 20804502 Free PMC article.
A phase I-II study of alpha-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer.
Motohashi S, Nagato K, Kunii N, Yamamoto H, Yamasaki K, Okita K, Hanaoka H, Shimizu N, Suzuki M, Yoshino I, Taniguchi M, Fujisawa T, Nakayama T. Motohashi S, et al. Among authors: yamasaki k. J Immunol. 2009 Feb 15;182(4):2492-501. doi: 10.4049/jimmunol.0800126. J Immunol. 2009. PMID: 19201905 Clinical Trial.
Migration and immunological reaction after the administration of αGalCer-pulsed antigen-presenting cells into the submucosa of patients with head and neck cancer.
Kurosaki M, Horiguchi S, Yamasaki K, Uchida Y, Motohashi S, Nakayama T, Sugimoto A, Okamoto Y. Kurosaki M, et al. Among authors: yamasaki k. Cancer Immunol Immunother. 2011 Feb;60(2):207-15. doi: 10.1007/s00262-010-0932-z. Epub 2010 Oct 27. Cancer Immunol Immunother. 2011. PMID: 20978887 Free PMC article. Clinical Trial.
Accumulation of activated invariant natural killer T cells in the tumor microenvironment after α-galactosylceramide-pulsed antigen presenting cells.
Nagato K, Motohashi S, Ishibashi F, Okita K, Yamasaki K, Moriya Y, Hoshino H, Yoshida S, Hanaoka H, Fujii S, Taniguchi M, Yoshino I, Nakayama T. Nagato K, et al. Among authors: yamasaki k. J Clin Immunol. 2012 Oct;32(5):1071-81. doi: 10.1007/s10875-012-9697-9. Epub 2012 Apr 26. J Clin Immunol. 2012. PMID: 22534863 Clinical Trial.
CD45RA-Foxp3high regulatory T cells have a negative impact on the clinical outcome of head and neck squamous cell carcinoma.
Ihara F, Sakurai D, Horinaka A, Makita Y, Fujikawa A, Sakurai T, Yamasaki K, Kunii N, Motohashi S, Nakayama T, Okamoto Y. Ihara F, et al. Among authors: yamasaki k. Cancer Immunol Immunother. 2017 Oct;66(10):1275-1285. doi: 10.1007/s00262-017-2021-z. Epub 2017 May 27. Cancer Immunol Immunother. 2017. PMID: 28551813 Free PMC article.
Regulatory T cells induce CD4- NKT cell anergy and suppress NKT cell cytotoxic function.
Ihara F, Sakurai D, Takami M, Kamata T, Kunii N, Yamasaki K, Iinuma T, Nakayama T, Motohashi S, Okamoto Y. Ihara F, et al. Among authors: yamasaki k. Cancer Immunol Immunother. 2019 Dec;68(12):1935-1947. doi: 10.1007/s00262-019-02417-6. Epub 2019 Oct 22. Cancer Immunol Immunother. 2019. PMID: 31641795 Free PMC article.
1,745 results